MD1718Z - Метод лечения тромбоза воротной вены у больных с циррозом печени - Google Patents
Метод лечения тромбоза воротной вены у больных с циррозом печени Download PDFInfo
- Publication number
- MD1718Z MD1718Z MDS20220090A MDS20220090A MD1718Z MD 1718 Z MD1718 Z MD 1718Z MD S20220090 A MDS20220090 A MD S20220090A MD S20220090 A MDS20220090 A MD S20220090A MD 1718 Z MD1718 Z MD 1718Z
- Authority
- MD
- Moldova
- Prior art keywords
- solution
- catheter
- needle
- spleen
- portal vein
- Prior art date
Links
- 201000009454 Portal vein thrombosis Diseases 0.000 title claims abstract description 18
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 14
- 210000000952 spleen Anatomy 0.000 claims abstract description 20
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 16
- 210000003240 portal vein Anatomy 0.000 claims abstract description 15
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 14
- 230000003287 optical effect Effects 0.000 claims abstract description 10
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims abstract description 9
- 108010088751 Albumins Proteins 0.000 claims abstract description 8
- 102000009027 Albumins Human genes 0.000 claims abstract description 8
- 108010039627 Aprotinin Proteins 0.000 claims abstract description 8
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 8
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 8
- 108090000190 Thrombin Proteins 0.000 claims abstract description 8
- 229960004405 aprotinin Drugs 0.000 claims abstract description 8
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 8
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 229960004072 thrombin Drugs 0.000 claims abstract description 8
- 230000002537 thrombolytic effect Effects 0.000 claims abstract description 8
- 230000001732 thrombotic effect Effects 0.000 claims abstract description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 6
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 6
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 210000000955 splenic vein Anatomy 0.000 claims abstract description 6
- 238000012800 visualization Methods 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 15
- 229940127219 anticoagulant drug Drugs 0.000 claims description 8
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 230000003393 splenic effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000012276 Endovascular treatment Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000007631 vascular surgery Methods 0.000 abstract description 2
- 239000002872 contrast media Substances 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 31
- 208000007232 portal hypertension Diseases 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010047249 Venous thrombosis Diseases 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 239000003055 low molecular weight heparin Substances 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000010911 splenectomy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 206010056091 Varices oesophageal Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000024170 esophageal varices Diseases 0.000 description 2
- 201000010120 esophageal varix Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
- 206010051012 Gastric varices Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009739 chronic venous congestion Effects 0.000 description 1
- 208000016598 congestive splenomegaly Diseases 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Изобретение относится к медицине, в частности к сосудистой хирургии и гепатологии, и может быть использовано для эндоваскулярного лечения тромбоза воротной вены у пациентов с циррозом печени. Сущность изобретения состоит в том, что выполняют доступ в подпупочной области с введением оптического устройства и доступ под край левой реберной дуги, в проекции селезенки, с введением троакара диаметром 5 мм, через который под визуализацией с оптическим устройством вводят иглу с тупым концом, длиной 15…20 см и диаметром 2…3 мм, которую вводят в паренхиму селезенки. Затем через иглу вводят контрастное вещество и под рентгенологическим контролем вводят иглу в одну внутриселезеночную венозную ветвь. Через упомянутую иглу вводят катетер на проводнике, который проходит через упомянутую венозную ветвь, затем через селезеночную вену и воротную вену, до зоны локализации тромба. После чего удаляют проводник и аспирируют тромботические массы, а через катетер вводят тромболитические и антикоагулянтные препараты. Затем катетер подтягивают до уровня ворот селезенки, а одновременно с его экстракцией через сформированный канал вводят два компонента фибринового клея, а именно первый компонент включает раствор фибриногена 15…45 мг, а второй компонент включает смесь раствора тромбина 25…100 ЕД, 10%-го раствора альбумина 10...20 мл, раствора апротинина 250…1000 КИЕ и раствора хлорида Са2+ 15...30 мкмоль, с пломбированием канала из паренхимы селезенки. После чего удаляют катетер и раны ушивают.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20220090A MD1718Z (ru) | 2022-11-08 | 2022-11-08 | Метод лечения тромбоза воротной вены у больных с циррозом печени |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20220090A MD1718Z (ru) | 2022-11-08 | 2022-11-08 | Метод лечения тромбоза воротной вены у больных с циррозом печени |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1718Y MD1718Y (ru) | 2023-09-30 |
| MD1718Z true MD1718Z (ru) | 2024-04-30 |
Family
ID=88236921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20220090A MD1718Z (ru) | 2022-11-08 | 2022-11-08 | Метод лечения тромбоза воротной вены у больных с циррозом печени |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1718Z (ru) |
-
2022
- 2022-11-08 MD MDS20220090A patent/MD1718Z/ru active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MD1718Y (ru) | 2023-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lunderquist et al. | Follow-up of patients with portal hypertension and esophageal varices treated with percutaneous obliteration of gastric coronary vein | |
| Loffroy et al. | Transcatheter arterial embolization for acute nonvariceal upper gastrointestinal bleeding: indications, techniques and outcomes | |
| Jorens et al. | Nonthrombotic pulmonary embolism | |
| Greenstein et al. | Acute hemorrhage associated with pancreatic pseudocysts | |
| Sandblom et al. | Hepatic hemobilia: hemorrhage from the intrahepatic biliary tract, a review | |
| Lefkovitz et al. | Radiology in the diagnosis and therapy of gastrointestinal bleeding | |
| Ohnishi et al. | Formation of hilar collaterals or cavernous transformation after portal vein obstruction by hepatocellular carcinoma: Observations in ten patients | |
| Foutch et al. | Colonic variceal hemorrhage after endoscopic injection sclerosis of esophageal varices: a report of three cases. | |
| Park et al. | Transcatheter arterial embolization for gastrointestinal bleeding associated with gastric carcinoma: prognostic factors predicting successful hemostasis and survival | |
| Al-Osaimi et al. | Medical and endoscopic management of gastric varices | |
| LONGMIRE JR et al. | Elective hepatic surgery | |
| Vujic et al. | Angiography and therapeutic blockade in the control of hemoptysis. The importance of nonbronchial systemic arteries. | |
| Lunderquist et al. | Sclerosing injection of esophageal varices through transhepatic selective catheterization of the gastric coronary vein: A preliminary report | |
| Winter et al. | Massive hemoptysis: pathogenesis and management | |
| CAHOW et al. | Hemobilia following percutaneous transhepatic cholangiography | |
| Sun et al. | Outcomes comparison between percutaneous decannulation with perclose ProGlide and surgical decannulation of veno-arterial extracorporeal membrane oxygenation | |
| MD1718Z (ru) | Метод лечения тромбоза воротной вены у больных с циррозом печени | |
| LANG | The role of arteriography in trauma | |
| Yamamoto et al. | Secondary hemocholecyst after radiofrequency ablation therapy for hepatocellular carcinoma | |
| Tashi et al. | Vascular complications related to image-guided percutaneous thermal ablation of hepatic tumors | |
| Henderson et al. | Percutaneous transhepatic occlusion for bleeding oesophageal varices | |
| RAHIMTOOLA et al. | Therapeutic defibrination and heparin therapy in the prevention and resolution of experimental venous thrombosis | |
| Bhargava et al. | Comparative efficacy of emergency endoscopic sclerotherapy for active variceal bleeding due to cirrhosis of the liver, non‐cirrhotic portal fibrosis and extrahepatic portal venous obstruction | |
| Kwon et al. | Transcatheter Arterial Embolisation of Acute Nonvariceal Upper Gastrointestinal Bleeding Refractory to Endoscopic Haemostasis | |
| MD1712Z (ru) | Метод уменьшении портальной гипертензии для лечения пациентов с циррозом печени |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued |